Targeting ACKR3/CXCR7 enhances platelet anticoagulant acylcarnitines and modulates procoagulant function.
Targeting ACKR3/CXCR7 regulates enzymatic generation of prothrombotic lipids while favoring antithrombotic lipids that inhibit platelets through the AC-cAMP-PKA pathway in coordination with prostacyclin IP receptor. This investigation validated the effect of CXCR7 in modulating nonenzymatic lipid (per)oxidation, platelet response to lipoproteins, mitochondrial metabolism, and procoagulant functions. CXCR7 agonist VUF11207 preserved mitochondrial membrane integrity, counteracted activation-induced mitochondrial superoxide generation, and reduced nonenzymatic lipid (per)oxidation. Moreover, it regulated lipoprotein-induced platelet adhesion to thrombogenic matrices, degranulation, αIIbβIII-integrin activation, aggregation, and thrombotic responses by reducing lipoprotein uptake through CD36 and ApoER2. CXCR7 ligation triggered the activation of AMP-dependent kinaseSer-172 and prompted AMPK-mediated inhibitory phosphorylation of acetyl-coenzyme A carboxylaseSer-79 to foster lipolysis over lipogenesis. Consequently, the AMPKSer-172-ACCSer-79 pathway increased generation of anticoagulant FXa-inhibitory long-chain acylcarnitines (LC-CAR) in platelets of healthy subjects and patients with coronary artery disease. Enrichment of intraplatelet LC-CARs was not attributable to dysregulated mitochondrial respiration because VUF11207 improved maximal respiration, spare respiratory capacity, and ATP-linked respiration in thrombin-activated platelets, suggesting sustained mitochondrial metabolism. Exerting a 2-pronged effect on procoagulant function, VUF11207 downregulated phosphatidylserine exposure on activated platelets and reduced FX/FXa binding, while platelet-derived anticoagulant LC-CARs regulated thrombin generation. VUF11207 administration reduced thrombus formation, platelet degranulation, αIIbβIII-integrin activation, procoagulant activity, and circulating platelet-leukocyte aggregates in murine venous thrombosis model, also decreased plasma procoagulant lipids derived from platelet cyclooxygenase-1 and 12-lipooxygenase (LOX), and leukocyte 5/15-LOX, decreased thromboinflammatory mediators (IL-1β, IL-6, IFN-γ, TNF-α, and MCP-1), and increased plasma LC-CAR levels. Therefore, pharmacological targeting of CXCR7 could regulate (non)enzymatic lipid processing and promote anticoagulant LC-CAR generation to limit platelet-driven thrombotic propensity and hypercoagulability, also replenish reduced levels of circulatory LC-CARs in patients with STEMI and VTE.